<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp>, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, and platelet activation are involved in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and its complications </plain></SENT>
<SENT sid="1" pm="."><plain>Soluble CD36 (sCD36) has been proposed to early identify diabetics at risk of accelerated atherothrombosis </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed at characterizing the platelet contribution to sCD36 in <z:mp ids='MP_0002055'>diabetes</z:mp>, by correlating its concentration with the extent of platelet-mediated <z:mp ids='MP_0001845'>inflammation</z:mp> and in vivo <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation and investigating the effects of low-dose aspirin on these processes </plain></SENT>
<SENT sid="3" pm="."><plain>A cross-sectional comparison of sCD36, soluble CD40L (sCD40L) reflecting platelet-mediated <z:mp ids='MP_0001845'>inflammation</z:mp>, urinary 11-dehydro-TxB(2), and 8-iso-<z:chebi fb="0" ids="26340">PGF</z:chebi>(2α), in vivo markers of platelet activation and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, was performed among 200 diabetic patients (94 of them on aspirin 100mg/day) and 47 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>sCD36 levels (median [IQR]: 0.72 [0.31-1.47] vs 0.26 [0.2-0.37], P=0.003) and urinary 11-dehydro-TxB(2) levels (666 [293-1336] vs 279 [160-396], P≤0.0001) were significantly higher in diabetic patients not on aspirin (n=106) than in healthy subjects </plain></SENT>
<SENT sid="5" pm="."><plain>These variables were significantly lower in aspirin-treated diabetics than untreated patients (P&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>Among patients not on aspirin, those with long-standing <z:mp ids='MP_0002055'>diabetes</z:mp> (&gt;1 year) had significantly higher sCD36 levels in comparison to patients with <z:mp ids='MP_0002055'>diabetes</z:mp> duration &lt;1 year (1.01 [0.62-1.86] vs 0.44 [0.22-1.21], P=0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>sCD36 linearly correlated with sCD40L (rho=0.447; P=0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>On multiple regression analysis, 11-dehydro-TxB(2) (β=0.360; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>=0.0001, P=0.001), 8-iso-<z:chebi fb="0" ids="26340">PGF</z:chebi>(2α) (β=0.469; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>=0.0001, P&lt;0.0001), and <z:mp ids='MP_0002055'>diabetes</z:mp> duration (β=0.244; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>=0.207, P=0.017) independently predicted sCD36 levels </plain></SENT>
<SENT sid="9" pm="."><plain>sCD36, platelet activation, <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:mp ids='MP_0003674'>oxidative stress</z:mp> are increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Future studies are needed to elucidate if the incomplete down-regulation of sCD36 by low-dose aspirin implies that sCD36 may be derived from tissues other than platelets or if additional antiplatelet strategies in <z:mp ids='MP_0002055'>diabetes</z:mp> are necessary to interrupt CD36-dependent platelet activation </plain></SENT>
</text></document>